このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus

2020年10月11日 更新者:Janine Alessi、Federal University of Rio Grande do Sul

Impact of Tele-Interventions During the COVID-19 Pandemic on Glycemic Control and Attitude Toward the Disease in Patients With Diabetes Mellitus - A Randomized Clinical Trial

INTRODUCTION In critical situations, such as the current COVID 19 pandemic, themes of fear, uncertainty and stigmatization are common and constitute barriers to appropriate medical and mental health interventions. These challenges, when faced by those who live with a chronic disease, such as diabetes mellitus (DM), can negatively influence quality of life and adherence to treatment, compromising the control of the disease.

OBJECTIVES The present study aims to investigate the effectiveness of a tele-intervention during the COVID-19 pandemic in improving glycemic control, lipid profile, blood pressure levels and parameters of medication adherence, mental well-being and sleep quality in patients with type 1 DM and type 2 DM.

METHODS A randomized clinical trial will be carried out with patients with a previous diagnosis of type 1 DM and type 2 DM, who are registered at the Hospital de Clínicas de Porto Alegre (HCPA). Inclusion criteria will be age greater than or equal to 18 years, collection of HbA1c in the HCPA laboratory in January, February or March 2020 and availability to receive weekly phone calls. Patients will be randomized, stratified by type of diabetes, in two groups: G1: participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the social distancing period ; G2: participants will receive the usual care. The primary outcome assessed will be the variation in HbA1c levels comparatively between groups, with or without a tele-guided strategy, after four months of social distancing (or as long as the recommendation of social distancing measures remains). Secondary outcomes will include experiencing confirmation of COVID-19 infection, variation in lipid profile, blood pressure levels and variation in parameters of emotional distress related to diabetes, eating disorders, medication adherence, symptoms minor psychiatric disorders and altered sleep patterns, which will be evaluated with specific and validated scales. According to the sample calculation, 150 patients will be included in the study (92 with type 2 DM and 58 with type 1 DM). Analysis by intention to treat will be performed separately for patients with type 1 DM and with type 2 DM.

SCHEDULE The proposed experiment will start immediately after approval of this project by the research ethics committee. The duration of the proposed intervention is 4 months (or as long as the recommendation of social distancing measures remains. This means that the study may be completed before or after that period, based on national recommendations for social distancing in Brazil), with a data analysis plan and publication of the results until September 2020.

調査の概要

研究の種類

介入

入学 (実際)

149

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Rio Grande Do Sul
      • Porto Alegre、Rio Grande Do Sul、ブラジル、90620-170
        • Hospital de Clinicas de Porto Alegre

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Type 1 diabetes mellitus or type 2 diabetes mellitus;
  • Age greater than or equal to 18 years;
  • HbA1c assessed in January, February or March 2020;
  • Availability to receive weekly phone calls

Exclusion Criteria:

  • Any severe cognitive limitation that prevents the necessary interaction to carry out this study (advanced dementia, deafness, dysarthria, aphasia);
  • Do not present a telephone record in an electronic medical record;

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:支持療法
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Tele-Intervention
Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
介入なし:Usual Care
Participants will receive the usual care

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Variation in HbA1c levels
時間枠:4 months (or as long as the recommendation of social distancing measures remains)
Variation in HbA1c levels comparatively between groups after the period of social distancing measures.
4 months (or as long as the recommendation of social distancing measures remains)

二次結果の測定

結果測定
メジャーの説明
時間枠
COVID-19 infection
時間枠:4 months (or as long as the recommendation of social distancing measures remains)
Confirmation of coronavirus infection by rapid test
4 months (or as long as the recommendation of social distancing measures remains)
Variation in lipid profile
時間枠:4 months (or as long as the recommendation of social distancing measures remains)
Comparison of the lipid profile of the last year with the lipid profile after the intervention between the groups.
4 months (or as long as the recommendation of social distancing measures remains)
Variation in blood pressure levels
時間枠:4 months (or as long as the recommendation of social distancing measures remains)
Comparison of the blood pressure level of the last consultation with the pressure after the intervention between the groups.
4 months (or as long as the recommendation of social distancing measures remains)
Comparison of emotional distress associated with the routine of living with diabetes after intervention between groups
時間枠:4 months (or as long as the recommendation of social distancing measures remains)
Evaluation of emotional distress associated with the routine of living with diabetes - B-PAID (Brazilian Problem Areas In Diabetes Scale)
4 months (or as long as the recommendation of social distancing measures remains)
Comparison of eating disorders between groups
時間枠:4 months (or as long as the recommendation of social distancing measures remains)
Evaluation of eating disorders - EAT - 26 SCALE (Teste de Atitudes Alimentares)
4 months (or as long as the recommendation of social distancing measures remains)
Comparison of adherence to the proposed clinical treatment between groups
時間枠:4 months (or as long as the recommendation of social distancing measures remains)
Evaluation of adherence to the proposed clinical treatment - SCI R (Self-Care Inventory - revised)
4 months (or as long as the recommendation of social distancing measures remains)
Comparison of minor psychiatric disorders between groups
時間枠:4 months (or as long as the recommendation of social distancing measures remains)
Evaluation of minor psychiatric disorders - SRQ 20 (Self Report Questionnaire)
4 months (or as long as the recommendation of social distancing measures remains)
Comparison of sleep pattern changes between groups
時間枠:4 months (or as long as the recommendation of social distancing measures remains)
Evaluation of sleep pattern changes - MSQ (Mini Sleep Questionnaire)
4 months (or as long as the recommendation of social distancing measures remains)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2020年4月17日

一次修了 (実際)

2020年9月20日

研究の完了 (実際)

2020年9月20日

試験登録日

最初に提出

2020年4月7日

QC基準を満たした最初の提出物

2020年4月10日

最初の投稿 (実際)

2020年4月14日

学習記録の更新

投稿された最後の更新 (実際)

2020年10月14日

QC基準を満たした最後の更新が送信されました

2020年10月11日

最終確認日

2020年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する